Q2-osavuosiraportti
91 päivää sitten‧15 min
Tarjoustasot
First North Sweden
Määrä
Osto
1 987
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,36VWAP
Alin
2,24VaihtoMäärä
0,2 85 493
VWAP
Ylin
2,36Alin
2,24VaihtoMäärä
0,2 85 493
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| Merkintäoikeusanti | 26.6. | |
| 2024 Yhtiökokous | 29.4. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q2-osavuosiraportti | 27.8.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
19 t sitten19 t sittenBioStock News: Next generation obesity drugs: How Pila Pharma could have a lucrative first-mover advantage https://biostock.se/2025/11/nasta-generations-obesitaslakemedel-pila-pharma-siktar-pa-lukrativt-first-mover-advantage/
·1 päivä sittenIs anyone following Pila closely? What can Pila in relation to Gudbra?·19 t sitten · MuokattuGubra (Gut-Brain) is primarily a company that conducts animal studies for other companies (contract research). In parallel, they have themselves experimented with creating molecules and development, i.e., a biotech division. Here they primarily produce peptides, i.e., biological drugs that target gastrointestinal hormones. Their goal, at least officially, is to drive the development of new molecules to proof-of-concept and then out-license or sell them. Gubra has the advantage that they are net-positive on revenue from contract research, but hampered by the fact that they develop molecules for a segment that is becoming increasingly saturated with GLP-1 and amylin solutions. PILA is a pure biotech company that has an alternative approach by wanting to inhibit the TRPV1 receptor, which is located on all sensory nerves and directly regulates inflammation. PILA's distinct goal is to prove that this receptor actually has a role to play in regulating metabolism, in order to then potentially enter into a partnership or be acquired. So far, no one else in the sector is immediately looking at TRPV1, and PILA therefore has an immediately attractive position but with the financing risk that follows biotech companies without revenue. Summary: Same (obesity) market - completely different approaches - completely different valuations - great opportunities in both :)- ·14.11.New dedicated Pila discord chat server if you want to discuss (constructively) with others 😃🧡 https://discord.gg/6USAdaSXZ
·21.11.I think there's a lot of "noise" on that Discord thread - please do let me know if anything substantial comes up there - ·5.11.New podcast (Danish) by Unge Aktionærer (Dansk Aktionær Forening): PILA PHARMA: Next acquisition candidate in the obesity market? In this episode, we have Gustav Hanghøj Gram in the studio, who is CEO of the Swedish-listed biotech company, PILA PHARMA, which is engaged in the development of a weight loss pill that differentiates itself from recognized preparations. In the episode, we talk about Gustav’s background, PILA PHARMA as a company in the past and currently, and then we delve into the obesity market and what role PILA PHARMA can potentially play in the growing market. https://podcasts.apple.com/lu/podcast/pila-pharma-n%C3%A6ste-opk%C3%B8bskandidat-i-fedmemarkedet/id1837654780?i=1000733820053·6.11.That must be a treat for Gubra :-)
·10.11. · MuokattuThe price in Pila is still 75 % below the offering price, and has therefore fallen steadily, and therefore does not seem like a success to build upon for other companies, regardless of what Pila might have in its medical treasure chest. Collaboration yes, as initiated with Gubra, but acquisition no. - 5.11.5.11.BioStock News: Pila Pharma stands out in next-generation obesity pipeline https://biostock.se/en/2025/11/pila-pharma-sticker-ut-bland-nasta-generations-fetmabehandlingar/Poistettu·5.11.Poistettu·5.11.It is a paid article, so it is as uninteresting as it can get. "SPONSORED CONTENT" "The content in BioStock's news and analyses is independent, but BioStock's operations are to some extent financed by companies in the industry. This post concerns a company from which BioStock has received funding."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
91 päivää sitten‧15 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 19 t sitten19 t sittenBioStock News: Next generation obesity drugs: How Pila Pharma could have a lucrative first-mover advantage https://biostock.se/2025/11/nasta-generations-obesitaslakemedel-pila-pharma-siktar-pa-lukrativt-first-mover-advantage/
- ·1 päivä sittenIs anyone following Pila closely? What can Pila in relation to Gudbra?·19 t sitten · MuokattuGubra (Gut-Brain) is primarily a company that conducts animal studies for other companies (contract research). In parallel, they have themselves experimented with creating molecules and development, i.e., a biotech division. Here they primarily produce peptides, i.e., biological drugs that target gastrointestinal hormones. Their goal, at least officially, is to drive the development of new molecules to proof-of-concept and then out-license or sell them. Gubra has the advantage that they are net-positive on revenue from contract research, but hampered by the fact that they develop molecules for a segment that is becoming increasingly saturated with GLP-1 and amylin solutions. PILA is a pure biotech company that has an alternative approach by wanting to inhibit the TRPV1 receptor, which is located on all sensory nerves and directly regulates inflammation. PILA's distinct goal is to prove that this receptor actually has a role to play in regulating metabolism, in order to then potentially enter into a partnership or be acquired. So far, no one else in the sector is immediately looking at TRPV1, and PILA therefore has an immediately attractive position but with the financing risk that follows biotech companies without revenue. Summary: Same (obesity) market - completely different approaches - completely different valuations - great opportunities in both :)
- ·14.11.New dedicated Pila discord chat server if you want to discuss (constructively) with others 😃🧡 https://discord.gg/6USAdaSXZ·21.11.I think there's a lot of "noise" on that Discord thread - please do let me know if anything substantial comes up there
- ·5.11.New podcast (Danish) by Unge Aktionærer (Dansk Aktionær Forening): PILA PHARMA: Next acquisition candidate in the obesity market? In this episode, we have Gustav Hanghøj Gram in the studio, who is CEO of the Swedish-listed biotech company, PILA PHARMA, which is engaged in the development of a weight loss pill that differentiates itself from recognized preparations. In the episode, we talk about Gustav’s background, PILA PHARMA as a company in the past and currently, and then we delve into the obesity market and what role PILA PHARMA can potentially play in the growing market. https://podcasts.apple.com/lu/podcast/pila-pharma-n%C3%A6ste-opk%C3%B8bskandidat-i-fedmemarkedet/id1837654780?i=1000733820053·6.11.That must be a treat for Gubra :-)·10.11. · MuokattuThe price in Pila is still 75 % below the offering price, and has therefore fallen steadily, and therefore does not seem like a success to build upon for other companies, regardless of what Pila might have in its medical treasure chest. Collaboration yes, as initiated with Gubra, but acquisition no.
- 5.11.5.11.BioStock News: Pila Pharma stands out in next-generation obesity pipeline https://biostock.se/en/2025/11/pila-pharma-sticker-ut-bland-nasta-generations-fetmabehandlingar/Poistettu·5.11.Poistettu·5.11.It is a paid article, so it is as uninteresting as it can get. "SPONSORED CONTENT" "The content in BioStock's news and analyses is independent, but BioStock's operations are to some extent financed by companies in the industry. This post concerns a company from which BioStock has received funding."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 987
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,36VWAP
Alin
2,24VaihtoMäärä
0,2 85 493
VWAP
Ylin
2,36Alin
2,24VaihtoMäärä
0,2 85 493
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| Merkintäoikeusanti | 26.6. | |
| 2024 Yhtiökokous | 29.4. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q2-osavuosiraportti | 27.8.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
91 päivää sitten‧15 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| Merkintäoikeusanti | 26.6. | |
| 2024 Yhtiökokous | 29.4. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q2-osavuosiraportti | 27.8.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 19 t sitten19 t sittenBioStock News: Next generation obesity drugs: How Pila Pharma could have a lucrative first-mover advantage https://biostock.se/2025/11/nasta-generations-obesitaslakemedel-pila-pharma-siktar-pa-lukrativt-first-mover-advantage/
- ·1 päivä sittenIs anyone following Pila closely? What can Pila in relation to Gudbra?·19 t sitten · MuokattuGubra (Gut-Brain) is primarily a company that conducts animal studies for other companies (contract research). In parallel, they have themselves experimented with creating molecules and development, i.e., a biotech division. Here they primarily produce peptides, i.e., biological drugs that target gastrointestinal hormones. Their goal, at least officially, is to drive the development of new molecules to proof-of-concept and then out-license or sell them. Gubra has the advantage that they are net-positive on revenue from contract research, but hampered by the fact that they develop molecules for a segment that is becoming increasingly saturated with GLP-1 and amylin solutions. PILA is a pure biotech company that has an alternative approach by wanting to inhibit the TRPV1 receptor, which is located on all sensory nerves and directly regulates inflammation. PILA's distinct goal is to prove that this receptor actually has a role to play in regulating metabolism, in order to then potentially enter into a partnership or be acquired. So far, no one else in the sector is immediately looking at TRPV1, and PILA therefore has an immediately attractive position but with the financing risk that follows biotech companies without revenue. Summary: Same (obesity) market - completely different approaches - completely different valuations - great opportunities in both :)
- ·14.11.New dedicated Pila discord chat server if you want to discuss (constructively) with others 😃🧡 https://discord.gg/6USAdaSXZ·21.11.I think there's a lot of "noise" on that Discord thread - please do let me know if anything substantial comes up there
- ·5.11.New podcast (Danish) by Unge Aktionærer (Dansk Aktionær Forening): PILA PHARMA: Next acquisition candidate in the obesity market? In this episode, we have Gustav Hanghøj Gram in the studio, who is CEO of the Swedish-listed biotech company, PILA PHARMA, which is engaged in the development of a weight loss pill that differentiates itself from recognized preparations. In the episode, we talk about Gustav’s background, PILA PHARMA as a company in the past and currently, and then we delve into the obesity market and what role PILA PHARMA can potentially play in the growing market. https://podcasts.apple.com/lu/podcast/pila-pharma-n%C3%A6ste-opk%C3%B8bskandidat-i-fedmemarkedet/id1837654780?i=1000733820053·6.11.That must be a treat for Gubra :-)·10.11. · MuokattuThe price in Pila is still 75 % below the offering price, and has therefore fallen steadily, and therefore does not seem like a success to build upon for other companies, regardless of what Pila might have in its medical treasure chest. Collaboration yes, as initiated with Gubra, but acquisition no.
- 5.11.5.11.BioStock News: Pila Pharma stands out in next-generation obesity pipeline https://biostock.se/en/2025/11/pila-pharma-sticker-ut-bland-nasta-generations-fetmabehandlingar/Poistettu·5.11.Poistettu·5.11.It is a paid article, so it is as uninteresting as it can get. "SPONSORED CONTENT" "The content in BioStock's news and analyses is independent, but BioStock's operations are to some extent financed by companies in the industry. This post concerns a company from which BioStock has received funding."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 987
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,36VWAP
Alin
2,24VaihtoMäärä
0,2 85 493
VWAP
Ylin
2,36Alin
2,24VaihtoMäärä
0,2 85 493
Välittäjätilasto
Dataa ei löytynyt